Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 216

Results For "PLI"

3556 News Found

NHA introduces new system to measure hospitals performance empaneled under AB PM-JAY Scheme
Policy | January 10, 2023

NHA introduces new system to measure hospitals performance empaneled under AB PM-JAY Scheme

The objective of this system is to shift the focus of measuring performance of hospitals from volume of services provided to value of healthcare services


Dr. Mandaviya inaugurates Annex Building of ICMR-RMRC, Bhubaneswar
News | January 09, 2023

Dr. Mandaviya inaugurates Annex Building of ICMR-RMRC, Bhubaneswar

The centre has initiated next generation sequencing (NGS) as a tool for undertaking studies on genomic epidemiology of pathogens


AIIMS Bhubaneswar provides quality healthcare service in Eastern India: Dr Mandaviya
News | January 09, 2023

AIIMS Bhubaneswar provides quality healthcare service in Eastern India: Dr Mandaviya

Dr. Mandaviya and Dharmendra Pradhan dedicate Burns Centre at AIIMS; Lays foundation stone of Critical Care Hospital Building, and award 40 gold medals to meritorious students


Protein found in Zebrafish can regenerate aged discs in human vertebrae
News | January 09, 2023

Protein found in Zebrafish can regenerate aged discs in human vertebrae

A study by Agharkar Research Institute (ARI), Pune, has discovered that a protein secreted from intervertebral disc cells induces disc regeneration in aged degenerated discs


Lupin receives approval from USFDA for Fesoterodine Fumarate Extended-Release Tablets
Drug Approval | January 07, 2023

Lupin receives approval from USFDA for Fesoterodine Fumarate Extended-Release Tablets

Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, (RLD Toviaz®) had estimated annual sales of USD 177 million in the U.S. (IQVIA MAT September 2022).


Alembic receives USFDA final approval for Fesoterodine Fumarate Extended-Release Tablets
Drug Approval | January 07, 2023

Alembic receives USFDA final approval for Fesoterodine Fumarate Extended-Release Tablets

Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, have an estimated market size of US$ 177 million for twelve months ending Sep 2022


Provention Bio appoints Rita Jain to Board of Directors
People | January 06, 2023

Provention Bio appoints Rita Jain to Board of Directors

Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co


PharmaEssentia sets up a new R&D facility in the Boston Area
News | January 05, 2023

PharmaEssentia sets up a new R&D facility in the Boston Area

The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation


Rupala to inaugurate 29 MVUs and centralised call center in Thiruvananthapuram
Healthcare | January 05, 2023

Rupala to inaugurate 29 MVUs and centralised call center in Thiruvananthapuram

MVUs will provide diagnosis treatment, vaccination, artificial insemination, minor surgical interventions, audio-visual aids and extension services to farmers/animal owners at their doorstep in far flung areas.